Cargando…

Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug

BACKGROUND: N-(6-(4-chlorophenoxy)hexyl)-N'-cyano-N''-4-pyridyl guanidine) (CHS 828) is the first candidate drug from a novel group of anti-tumour agents – the pyridyl cyanoguanidines, shown to be potent compounds interfering with cellular metabolism (inhibition of nicotinamide phosph...

Descripción completa

Detalles Bibliográficos
Autores principales: Lövborg, Henrik, Burman, Robert, Gullbo, Joachim
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709656/
https://www.ncbi.nlm.nih.gov/pubmed/19563661
http://dx.doi.org/10.1186/1756-0500-2-114
_version_ 1782169321223487488
author Lövborg, Henrik
Burman, Robert
Gullbo, Joachim
author_facet Lövborg, Henrik
Burman, Robert
Gullbo, Joachim
author_sort Lövborg, Henrik
collection PubMed
description BACKGROUND: N-(6-(4-chlorophenoxy)hexyl)-N'-cyano-N''-4-pyridyl guanidine) (CHS 828) is the first candidate drug from a novel group of anti-tumour agents – the pyridyl cyanoguanidines, shown to be potent compounds interfering with cellular metabolism (inhibition of nicotinamide phosphoribosyl transferase) and NF-κB signalling. Substituted cyanoguanidines are also found in anti-hypertensive agents such as the potassium channel opener pinacidil (N-cyano-N'-(4-pyridyl)-N''-(1,2,2-trimethylpropyl)guanidine) and histamine-II receptor antagonists (e.g. cimetidine, N-cyano-N'-methyl-N''-[2-[[(5-methylimidazol-4-yl]methyl]thio]ethyl)guanidine). In animal studies, CHS 828 has shown very promising activity, and phase I and II studies resulted in further development of a with a water soluble prodrug. FINDINGS: To study the structural requirements for cyanoguanidine cytotoxicity a set of 19 analogues were synthesized. The cytotoxic effects were then studied in ten cell lines selected for different origins and mechanisms of resistance, using the fluorometric microculture cytotoxicity assay (FMCA). The compounds showed varying cytotoxic activity even though the dose-response curves for some analogues were very shallow. Pinacidil and cimetidine were found to be non-toxic in all ten cell lines. Starting with cyanoguanidine as the crucial core it was shown that 4-pyridyl substitution was more efficient than was 3-pyridyl substitution. The 4-pyridyl cyanoguanidine moiety should be linked by an alkyl chain, optimally a hexyl, heptyl or octyl chain, to a bulky end group. The exact composition of this end group did not seem to be of crucial importance; when the end group was a mono-substituted phenyl ring it was shown that the preferred position was 4-substitution, followed by 3- and, finally, 2-substitution as the least active. Whether the substituent was a chloro, nitro or methoxy substituent seemed to be of minor importance. Finally, the activity patterns in the ten cell lines were compared. Substances with similar structures correlated well, whilst substances with large differences in molecular structure demonstrated lower correlation coefficients. CONCLUSION: According to this structure-activity relationship (SAR) study, CHS 828 meets the requirements for optimal cytotoxic activity for this class of compounds.
format Text
id pubmed-2709656
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27096562009-07-14 Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug Lövborg, Henrik Burman, Robert Gullbo, Joachim BMC Res Notes Short Report BACKGROUND: N-(6-(4-chlorophenoxy)hexyl)-N'-cyano-N''-4-pyridyl guanidine) (CHS 828) is the first candidate drug from a novel group of anti-tumour agents – the pyridyl cyanoguanidines, shown to be potent compounds interfering with cellular metabolism (inhibition of nicotinamide phosphoribosyl transferase) and NF-κB signalling. Substituted cyanoguanidines are also found in anti-hypertensive agents such as the potassium channel opener pinacidil (N-cyano-N'-(4-pyridyl)-N''-(1,2,2-trimethylpropyl)guanidine) and histamine-II receptor antagonists (e.g. cimetidine, N-cyano-N'-methyl-N''-[2-[[(5-methylimidazol-4-yl]methyl]thio]ethyl)guanidine). In animal studies, CHS 828 has shown very promising activity, and phase I and II studies resulted in further development of a with a water soluble prodrug. FINDINGS: To study the structural requirements for cyanoguanidine cytotoxicity a set of 19 analogues were synthesized. The cytotoxic effects were then studied in ten cell lines selected for different origins and mechanisms of resistance, using the fluorometric microculture cytotoxicity assay (FMCA). The compounds showed varying cytotoxic activity even though the dose-response curves for some analogues were very shallow. Pinacidil and cimetidine were found to be non-toxic in all ten cell lines. Starting with cyanoguanidine as the crucial core it was shown that 4-pyridyl substitution was more efficient than was 3-pyridyl substitution. The 4-pyridyl cyanoguanidine moiety should be linked by an alkyl chain, optimally a hexyl, heptyl or octyl chain, to a bulky end group. The exact composition of this end group did not seem to be of crucial importance; when the end group was a mono-substituted phenyl ring it was shown that the preferred position was 4-substitution, followed by 3- and, finally, 2-substitution as the least active. Whether the substituent was a chloro, nitro or methoxy substituent seemed to be of minor importance. Finally, the activity patterns in the ten cell lines were compared. Substances with similar structures correlated well, whilst substances with large differences in molecular structure demonstrated lower correlation coefficients. CONCLUSION: According to this structure-activity relationship (SAR) study, CHS 828 meets the requirements for optimal cytotoxic activity for this class of compounds. BioMed Central 2009-06-29 /pmc/articles/PMC2709656/ /pubmed/19563661 http://dx.doi.org/10.1186/1756-0500-2-114 Text en Copyright © 2009 Gullbo et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Lövborg, Henrik
Burman, Robert
Gullbo, Joachim
Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug
title Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug
title_full Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug
title_fullStr Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug
title_full_unstemmed Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug
title_short Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug
title_sort structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of chs 828 as candidate drug
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709656/
https://www.ncbi.nlm.nih.gov/pubmed/19563661
http://dx.doi.org/10.1186/1756-0500-2-114
work_keys_str_mv AT lovborghenrik structureactivityrelationshipanalysisofcytotoxiccyanoguanidinesselectionofchs828ascandidatedrug
AT burmanrobert structureactivityrelationshipanalysisofcytotoxiccyanoguanidinesselectionofchs828ascandidatedrug
AT gullbojoachim structureactivityrelationshipanalysisofcytotoxiccyanoguanidinesselectionofchs828ascandidatedrug